Sun Pharmaceutical Industries Limited reported financials for the first quarter ending June 30th, 2025. The company reported a 20% fall in its Q1 consolidated net profit to Rs. 2,278 crore compared to Rs. 2,836 crore in the year ago period.

The company's revenue from operation stood at Rs 13,786 crore which was up 10% versus Rs 12,525 crore posted in the corresponding quarter of the last financial year.

Formulation sales in India were Rs. 4,721.1 crore, up by 13.9%. India Formulation sales accounted for 34.2% of total consolidated sales for the quarter. Formulation sales in the US were US$ 473 million; accounting for over 29.3% of total consolidated sales.

Dilip Shanghvi, Chairman and Managing Director of the Company, said, "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business."

Sun Pharma’s R&D efforts span across both innovative and generic businesses and the company continues to invest in building the pipeline for various markets. Sun’s innovative R&D pipeline includes six novel entities in clinical stage. Sun has a comprehensive product offering in the US market consisting of approved ANDAs for 542 products while filings for 119 ANDAs await US FDA approval, including 33 tentative approvals. Additionally, the portfolio includes 57 approved NDAs while 13 NDAs await US FDA approval. For the quarter, 2 ANDA were filed and 1 ANDA approval was received.